NCT06243016 Breaking Sitting with High-intensity Interval Training for Brain Health
| NCT ID | NCT06243016 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Urbana-Champaign |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2024-05-07 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 54 participants in total. It began in 2024-05-07 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial will examine whether interrupting 3.5 hours of sitting every 30 min with 6 min high intensity interval training (HIIT) breaks compared to light intensity interval training (LIIT) will improve brain health in cognitively normal older adults. This trial will test the feasibility of HIIT breaks to sitting. It will also address several important but unanswered questions: (1) Does interrupting sitting with short HIIT breaks improve frontoparietal function? (2) Can interrupting sitting with HIIT breaks improve cognitive functions?
Eligibility Criteria
Inclusion Criteria: 1. Age 40-75 years 2. BMI \<40 kg/m2 3. Sedentary (≥ 6 h/day sitting by a survey question) 4. Physically inactive adults based on the CSEP-PATH: Physical Activity and Sedentayr Behaviour Questionnaire (PASB-Q) Adult (low or medium physical activity range equivalent to less than 300 min of moderate intensity physical activity per week) 5. Capable of exercising vigorously based on the Physical Activity Readiness Questionnaire (PARQ+) 6. Has a medical clearance for maximal exercise and HIIT from a physician 7. Normotensive or participant's blood pressure is controlled 8. Intelligence quotient (IQ) ≥85 9. Fasting plasma glucose \<126 mg/dL 10. Good or corrected vision and hearing 11. Right-handed 12. No significant abnormalities on the ECG during the maximal exercise test 13. No signs and symptoms that suggest an underlying cardiovascular disease as recorded during the maximal exercise test by a study physician. 14. No indications to prematurely stop the maximal exercise test as outlined by the ACSM's Guidelines for Exercise Testing and Prescription 15. Concussion if more than 12 months before the study screening. 16. History of cancer but in full remission for at least 12 months and no history of chemotherapy, signed off by the physician or an oncologist Exclusion Criteria: 1. Physical disability or musculoskeletal disease prohibitive to vigorous exercise 2. Learning disabilities 3. Cognitive impairment (MoCA \<26) 4. Type 1 or 2 diabetes 5. Neurological condition (e.g., Multiple Sclerosis, Parkinson, Dementia, Mild Cognitive Impairment) 6. Color blindness 7. Brain injury (e.g., traumatic brain injury, stroke, concussion) 8. Migraine headaches 9. Presence of other health conditions that may be exacerbated by exercise 10. History of heart disease 11. High cholesterol not controlled by medication 12. Signs and symptoms indicative of underlying cardiovascular disease 13. A chronic pulmonary disease 14. Emphysema 15. Pulmonary embolus 16. Asthma 17. History of renal disease 18. History of seizures 19. A neuropsychiatric disorder 20. Osteoporosis if it interferes with an individual's ability to exercise 21. Severe back problems 22. Severe arthritis if it interferes with an individual's ability to exercise 23. Thyroid disorder not controlled by medication 24. Polyneuropathy 25. Sleep disorders 26. Acquired immunodeficiency syndrome (AIDS) 27. Hepatitis C 28. History of long Coronavirus Disease 2019 (COVID-19) 29. History of cancer if not in full remission for at least 12 months and if a participant had the history of chemotherapy 30. Current or past smoking \<12 months 31. Corticosteroid intake \< 31 days before screening 32. Opioids taken \< 6 months from screening 33. Anabolic androgens taken \< 31 days before screening 34. A serious illness or hospitalization in the last six months 35. Currently taking medications that can affect the central nervous system (except for anxiolytics) 36. Current participation in an ongoing trial likely to influence exercise ability or cognitive function
Contact & Investigator
Dominika M Pindus, Ph.D.
PRINCIPAL INVESTIGATOR
University of Illinois Urbana-Champaign
Frequently Asked Questions
Who can join the NCT06243016 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06243016 currently recruiting?
Yes, NCT06243016 is actively recruiting participants. Contact the research team at pindus@illinois.edu for enrollment information.
Where is the NCT06243016 trial being conducted?
This trial is being conducted at Urbana, United States.
Who is sponsoring the NCT06243016 clinical trial?
NCT06243016 is sponsored by University of Illinois at Urbana-Champaign. The principal investigator is Dominika M Pindus, Ph.D. at University of Illinois Urbana-Champaign. The trial plans to enroll 54 participants.